Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited
( Jan 30, 2026 )
Both India and the EU stand to benefit significantly from the signing of the trade deal. For Indian pharmaceutical and biotechnology companies, it presents a major opportunity to expand access to high-quality, life-saving medicines, making them more affordable for a large segment of the patient population across the EU.





